Department of Pathophysiology, Faculty of Medicine, Medical University of Gdańsk, ul. Dębinki 7, 80-211, Gdańsk, Poland.
Department of Pathophysiology, Faculty of Medicine, Medical University of Gdańsk, ul. Dębinki 7, 80-211, Gdańsk, Poland.
Anaerobe. 2019 Oct;59:100-106. doi: 10.1016/j.anaerobe.2019.06.002. Epub 2019 Jun 5.
Lactulose is a disaccharide used in clinical practice since 1957 and has since been tested in the treatment of many human disorders, including chronic constipation, hepatic encephalopathy, and chronic kidney disease. Its mode of action is based on the lactulose fermentation by intestinal microbiota. Based on in silico, in vitro and in vivo studies we comprehensively review here the impact of lactulose on human gut/fecal and vaginal microbiota composition and both fecal and blood metabolomes. However, both in vitro and in vivo studies summarized in this review have revealed that the effects of lactulose on human microbiota composition are both patient- and dose-dependent. This highlights the need of heterogeneity indication in clinical trials.
乳果糖自 1957 年以来在临床实践中被使用，此后已在许多人类疾病的治疗中进行了测试，包括慢性便秘、肝性脑病和慢性肾脏病。它的作用模式基于肠道微生物群对乳果糖的发酵。基于计算机模拟、体外和体内研究，我们在这里全面综述了乳果糖对人类肠道/粪便和阴道微生物群组成以及粪便和血液代谢组的影响。然而，本综述中总结的体外和体内研究都表明，乳果糖对人类微生物群组成的影响既依赖于患者又依赖于剂量。这突出表明在临床试验中需要进行异质性指示。
